-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target

Benzinga·09/29/2026 17:46:51
Listen to the news
Piper Sandler analyst Edward Tenthoff reiterates Dyne Therapeutics (NASDAQ:DYN) with a Overweight and maintains $47 price target.